Advisory Resource Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-27,523
Closed -$1.4M 184
2025
Q4
$1.4M Buy
27,523
+5,007
+22% +$256K 0.25% 95
2025
Q3
$1.25M Buy
22,516
+7,362
+49% +$431K 0.22% 106
2025
Q2
$1.05M Buy
15,154
+651
+4% +$44.3K 0.2% 111
2025
Q1
$1.01M Buy
14,503
+2,518
+21% +$208K 0.21% 101
2024
Q4
$1.03M Buy
11,985
+4,544
+61% +$491K 0.22% 97
2024
Q3
$886K Sell
7,441
-27
-0.4% -$3.6K 0.19% 108
2024
Q2
$1.07M Buy
7,468
+151
+2% +$20K 0.24% 79
2024
Q1
$940K Buy
7,317
+823
+13% +$98K 0.22% 83
2023
Q4
$672K Sell
6,494
-489
-7% -$48.4K 0.17% 105
2023
Q3
$635K Buy
6,983
+27
+0.4% +$2.38K 0.17% 95
2023
Q2
$563K Sell
6,956
-650
-9% -$53.1K 0.15% 104
2023
Q1
$605K Sell
7,606
-674
-8% -$47.8K 0.17% 93
2022
Q4
$560K Buy
+8,280
New +$485K 0.17% 79
2022
Q3
Sell
-4,312
Closed -$240K 140
2022
Q2
$240K Sell
4,312
-868
-17% -$48.2K 0.08% 117
2022
Q1
$288K Buy
5,180
+398
+8% +$20.4K 0.09% 113
2021
Q4
$239K Buy
4,782
+572
+14% +$31K 0.08% 129
2021
Q3
$202K Sell
4,210
-596
-12% -$28.8K 0.07% 133
2021
Q2
$201K Buy
+4,806
New +$186K 0.08% 129

Other funds holding NVO

Advisory Resource Group's NVO Position: Q1 2026 in Review

Advisory Resource Group sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 27,523 shares — an estimated $1.4M sold.

Advisory Resource Group first reported a position in NVO in Q2 2021 and held it in 18 quarters. The position peaked at $1.4M in Q4 2025. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Advisory Resource Group reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Advisory Resource Group sold 27,523 Novo Nordisk shares in Q1 2026, an estimated $1.4M.
  • Advisory Resource Group first reported a position in Novo Nordisk in Q2 2021 and held it in 18 quarters.
  • Advisory Resource Group's Novo Nordisk position peaked at $1.4M in Q4 2025.
  • 1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Advisory Resource Group's 13F filing for Q1 2026, filed 15 May 2026.